Atara Biotherapeutics $175 million common stock and pre-funded warrants offering
12/11/2020

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $175 million SEC-registered common stock and pre-funded warrants offering by Atara Biotherapeutics, Inc. Atara’s common stock is listed on the Nasdaq Global Select Market under the symbol “ATRA.”

Based in South San Francisco, California, Atara is a pioneer in T-cell immunotherapy leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers and autoimmune diseases.

The Davis Polk corporate team included partners Alan F. Denenberg and Emily Roberts and associates Blake Anderson and Travis B. Mitchell. The tax team included partner Mario J. Verdolini and associate Shay Moyal. Partner Pritesh P. Shah and associate Jay Frankel provided intellectual property advice. Associate Matthew R. Silver provided 1940 Act advice. Members of the Davis Polk team are based in the Northern California and New York offices.